FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Lucien Aarden

Research Profile

Chemicals & Drugs

Anatomy

Co-author Network

Publications

TOP 3
Margreet H Hart; Joep Killestein; Lucien A Aarden; Els R de Groot; Henk de Vrieze; Gerrit-Jan Wolbink; Diana Wouters; Theo Rispens
Differential effect of drug interference in immunogenicity assays.
Marna G Bouwhuis; Sandra Collette; Els R de Groot; Alexander M M Eggermont; Wim H Kruit; Stefan Suciu; Antonius J G Swaak; Timo L M ten Hagen; Lucien A Aarden
Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome.
Theo Rispens; Astrid van Leeuwen; Anke Vennegoor; Joep Killestein; Rob C Aalberse; Gertjan Wolbink; Lucien A Aarden
Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Lucien Aarden (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Margreet H Hart; Joep Killestein; Lucien A Aarden; Els R de Groot; Henk de Vrieze; Gerrit-Jan Wolbink; Diana Wouters; Theo Rispens
Differential effect of drug interference in immunogenicity assays.
Journal of immunological methods 2011;372(1-2):196-203.
2011: Marna G Bouwhuis; Sandra Collette; Els R de Groot; Alexander M M Eggermont; Wim H Kruit; Stefan Suciu; Antonius J G Swaak; Timo L M ten Hagen; Lucien A Aarden
Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome.
Melanoma research 2011;21(4):344-51.
2011: Theo Rispens; Astrid van Leeuwen; Anke Vennegoor; Joep Killestein; Rob C Aalberse; Gertjan Wolbink; Lucien A Aarden
Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.
Analytical biochemistry 2011;411(2):271-6.
2011: Femke Stephan; Tom van der Poll; Jw Olivier van Till; Walter A Wuillemin; Lucien A Aarden; Marja A Boermeester; Ingrid Bulder; Jan A Hazelzet; Sacha Zeerleder
Activation of factor VII-activating protease in human inflammation: a sensor for cell death.
Critical care (London, England) 2011;15(2):R110.
2010: Annemieke Van Dijk; Rob A Vermond; P A J Krijnen; Lynda J M Juffermans; Nynke E Hahn; Sudesh P Makker; Lucien A Aarden; Erik Hack; Marieke Spreeuwenberg; Bert C van Rossum; Cristof Meischl; Walter J Paulus; Florine J van Milligen; Hans W M Niessen
Intravenous clusterin administration reduces myocardial infarct size in rats.
European journal of clinical investigation 2010;40(10):893-902.
2009: Carola W N Damen; Els R de Groot; Marianne Heij; David Boss; Jan H M Schellens; Hilde Rosing; Jos H Beijnen; Lucien A Aarden
Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma.
Analytical biochemistry 2009;391(2):114-20.
2009: Gerrit J Wolbink; Lucien A Aarden; B A C Dijkmans
Dealing with immunogenicity of biologicals: assessment and clinical relevance.
Current opinion in rheumatology 2009;21(3):211-5.
2009: M K de Vries; Irene E van der Horst-Bruinsma; Michael T Nurmohamed; Lucien A Aarden; S O Stapel; M J L Peters; J Christiaan van Denderen; B A C Dijkmans; Gertjan Wolbink
Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
Annals of the rheumatic diseases 2009;68(4):531-5.
2009: Diana Wouters; Pauline van Schouwenburg; Anneke van der Horst; Martin de Boer; Dennis Schooneman; Taco W Kuijpers; Lucien A Aarden; Dörte Hamann
High-throughput analysis of the C4 polymorphism by a combination of MLPA and isotype-specific ELISA's.
Molecular immunology 2009;46(4):592-600.
2008: Sacha Zeerleder; Bas Zwart; Henk te Velthuis; Femke Stephan; Rishi Manoe; Irma Rensink; Lucien A Aarden
Nucleosome-releasing factor: a new role for factor VII-activating protease (FSAP).
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2008;22(12):4077-84.
2008: Robert Kikkert; Els R de Groot; Lucien A Aarden
Cytokine induction by pyrogens: comparison of whole blood, mononuclear cells, and TLR-transfectants.
Journal of immunological methods 2008;336(1):45-55.
2008: Thomas Kuilman; Chrysiis Michaloglou; Liesbeth C W Vredeveld; Sirith Douma; Remco van Doorn; Christophe J Desmet; Lucien A Aarden; Wolter J Mooi; Daniel S Peeper
Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network.
Cell 2008;133(6):1019-31.
2007: Sacha Zeerleder; Bas Zwart; Henk te Velthuis; Rishi Manoe; Ingrid Bulder; Irma Rensink; Lucien A Aarden
A plasma nucleosome releasing factor (NRF) with serine protease activity is instrumental in removal of nucleosomes from secondary necrotic cells.
FEBS letters 2007;581(28):5382-8.
2007: Marijn van der Neut Kolfschoten; Janine Schuurman; Mario Losen; Wim K Bleeker; Pilar Martinez-Martinez; Ellen Vermeulen; Tamara H den Bleker; Luus Wiegman; Tom Vink; Lucien A Aarden; Marc H De Baets; Jan G J van de Winkel; Rob C Aalberse; Paul W H I Parren
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.
Science (New York, N.Y.) 2007;317(5844):1554-7.
2007: Mirjam K de Vries; Gertjan Wolbink; Steven O Stapel; Henk de Vrieze; J Christiaan van Denderen; B A C Dijkmans; Lucien A Aarden; Irene E van der Horst-Bruinsma
Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
Annals of the rheumatic diseases 2007;66(9):1252-4.
2007: Geertje M Bartelds; Carla A Wijbrandts; Michael T Nurmohamed; Steven O Stapel; Willem F Lems; Lucien A Aarden; B A C Dijkmans; Paul P Tak; Gertjan Wolbink
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.
Annals of the rheumatic diseases 2007;66(7):921-6.
2007: R Kikkert; M L Laine; Lucien A Aarden; A J van Winkelhoff
Activation of toll-like receptors 2 and 4 by gram-negative periodontal bacteria.
Oral microbiology and immunology 2007;22(3):145-51.
2007: C J van der Laken; Alexandre E Voskuyl; Jan C Roos; Marijke Stigter-van Walsum; Els R de Groot; Gertjan Wolbink; B A C Dijkmans; Lucien A Aarden
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis.
Annals of the rheumatic diseases 2007;66(2):253-6.
2007: Robert Kikkert; Ingrid Bulder; Els R de Groot; Lucien A Aarden; Malcolm Finkelman
Potentiation of Toll-like receptor-induced cytokine production by (1-->3)-beta-D-glucans: implications for the monocyte activation test.
Journal of endotoxin research 2007;13(3):140-9.
2007: M K de Vries; Gertjan Wolbink; Steven O Stapel; Els R de Groot; B A C Dijkmans; Lucien A Aarden; Irene E van der Horst-Bruinsma
Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
Annals of the rheumatic diseases 2007;66(1):133-4.
2006: Jan Van Till; Marja A Boermeester; Piet W Modderman; Johanna W van Sandick; Margreet H L Hart; Suzanne S Gisbertz; J J B van Lanschot; Lucien A Aarden
Variable mannose-binding lectin expression during postoperative acute-phase response.
Surgical infections 2006;7(5):443-52.
2006: G M Bartelds; Gertjan Wolbink; Steven O Stapel; Lucien A Aarden; Willem F Lems; B A C Dijkmans; Michael T Nurmohamed
High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment.
Annals of the rheumatic diseases 2006;65(9):1249-50.
2006: Nannette Brouwer; Koert M Dolman; Rob van Zwieten; Ed Nieuwenhuys; Margreet Hart; Lucien A Aarden; Dirk Roos; Taco W Kuijpers
Mannan-binding lectin (MBL)-mediated opsonization is enhanced by the alternative pathway amplification loop.
Molecular immunology 2006;43(13):2051-60.
2006: Gertjan Wolbink; Marijn Vis; Willem F Lems; Alexandre E Voskuyl; Els R de Groot; Michael T Nurmohamed; Steven O Stapel; Paul P Tak; Lucien A Aarden; B A C Dijkmans
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.
Arthritis and rheumatism 2006;54(3):711-5.
2005: P A J Krijnen; Saskia A G M Cillessen; Rishi Manoe; Alice Muller; Cees A Visser; C J L M Meijer; René J P Musters; C Erik Hack; Lucien A Aarden; Hans W M Niessen
Clusterin: a protective mediator for ischemic cardiomyocytes?
American journal of physiology. Heart and circulatory physiology 2005;289(5):H2193-202.
2005: Roy F M van der Putten; Henk te Velthuis; Chris de Zwaan; Lucien A Aarden; Jan F C Glatz; Wim T Hermens
State and diagnostic value of plasma tissue factor in early-hospitalised patients with chest pain.
British journal of haematology 2005;131(1):91-9.
2005: M M J Nielen; A R van der Horst; Dirkjan van Schaardenburg; Irene E van der Horst-Bruinsma; Rob J van de Stadt; Lucien A Aarden; B A C Dijkmans; D Hamann
Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.
Annals of the rheumatic diseases 2005;64(8):1199-204.
2005: Anja ten Brinke; David W C Dekkers; Silla M Notten; Miriam L Karsten; Els R de Groot; Lucien A Aarden
4-Hydroxy-oxyphenbutazone is a potent inhibitor of cytokine production.
European cytokine network 2005;16(2):144-51.
2005: Gertjan Wolbink; Alexandre E Voskuyl; Willem F Lems; Els R de Groot; Michael T Nurmohamed; Paul P Tak; B A C Dijkmans; Lucien A Aarden
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
Annals of the rheumatic diseases 2005;64(5):704-7.
2005: Roy F M van der Putten; Henk te Velthuis; Lucien A Aarden; Hugo ten Cate; Jan F C Glatz; Wim T Hermens
High-affinity antibodies in a new immunoassay for plasma tissue factor: reduction in apparent intra-individual variation.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2005;43(12):1386-91.
2004: Sacha de Lathouder; Andreas H Gerards; B A C Dijkmans; Lucien A Aarden
Two inhibitors of DNA-synthesis lead to inhibition of cytokine production via a different mechanism.
Nucleosides, nucleotides & nucleic acids 2004;23(8-9):1089-100.
2004: Bas Zwart; Caroline L F Ciurana; Irma Rensink; Rishi Manoe; C Erik Hack; Lucien A Aarden
Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells.
Autoimmunity 2004;37(2):95-102.
2004: Sacha de Lathouder; Andreas H Gerards; E R de Groot; M G Valkhof; B A C Dijkmans; Lucien A Aarden
Bioassay for detection of methotrexate in serum.
Scandinavian journal of rheumatology 2004;33(3):167-73.
2003: A N Tacx; A B Johan Groeneveld; Margreet H L Hart; Lucien A Aarden; C Erik Hack
Mannan binding lectin in febrile adults: no correlation with microbial infection and complement activation.
Journal of clinical pathology 2003;56(12):956-9.
2003: Andreas H Gerards; Sacha de Lathouder; Els R de Groot; B A C Dijkmans; Lucien A Aarden
Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis.
Rheumatology (Oxford, England) 2003;42(10):1189-96.
2003: Sacha Zeerleder; Bas Zwart; Walter A Wuillemin; Lucien A Aarden; A B Johan Groeneveld; Christoph Caliezi; Annemarie E M van Nieuwenhuijze; Gerard van Mierlo; Anke J M Eerenberg; Bernhard Lämmle; C Erik Hack
Elevated nucleosome levels in systemic inflammation and sepsis.
Critical care medicine 2003;31(7):1947-51.
2003: Annemarie E M van Nieuwenhuijze; T van Lopik; R J T Smeenk; Lucien A Aarden
Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus.
Annals of the rheumatic diseases 2003;62(1):10-4.
2002: Sacha de Lathouder; Andreas H Gerards; Els R de Groot; Marijke Valkhof; Lucien A Aarden
Mycophenolic acid and methotrexate inhibit lymphocyte cytokine production via different mechanisms.
European cytokine network 2002;13(3):317-23.
2001: Laura M Ribeiro-do-Couto; LC Boeije; J S Kroon; Berend Hooibrink; B S Breur-Vriesendorp; Lucien A Aarden; Claire J P Boog
High IL-13 production by human neonatal T cells: neonate immune system regulator?
European journal of immunology 2001;31(11):3394-402.
2001: A Familian; Bas Zwart; H G Huisman; Irma Rensink; Dorina Roem; Peter L Hordijk; Lucien A Aarden; C Erik Hack
Chromatin-independent binding of serum amyloid P component to apoptotic cells.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(2):647-54.
2001: Michiel W van der Linden; T van Lopik; Lucien A Aarden; Rudi G J Westendorp; Tom W J Huizinga
Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives.
Annals of the rheumatic diseases 2001;60(3):237-41.
2000: Hans W M Niessen; Wim Lagrand; H J Rensink; Chris J L M Meijer; Lucien A Aarden; C Erik Hack; C Visser
Apolipoprotein H, a new mediator in the inflammatory changes ensuring in jeopardised human myocardium.
Journal of clinical pathology 2000;53(11):863-7.
1999: A Civil; Irma Rensink; Lucien A Aarden; C L Verweij
Functional disparity of distinct CD28 response elements toward mitogenic responses.
The Journal of biological chemistry 1999;274(48):34369-74.
1999: Tineke C T M van der Pouw Kraan; Anneke van Veen; LC Boeije; S A van Tuyl; Els R de Groot; Steven O Stapel; Arjen Bakker; Cornelis L Verweij; Lucien A Aarden; jaring s. van der zee
An IL-13 promoter polymorphism associated with increased risk of allergic asthma.
Genes and immunity 1999;1(1):61-5.
1999: T van Lopik; Marc Bijl; Margreet Hart; LC Boeije; T Gesner; A A Creasy; Cees G M Kallenberg; Lucien A Aarden; R J T Smeenk
Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse.
The Journal of rheumatology 1999;26(1):60-7.
1998: HC van Zaanen; Henk M Lokhorst; Lucien A Aarden; H J Rensink; SO Warnaar; Marinus H J van Oers
Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.
Leukemia & lymphoma 1998;31(5-6):551-8.
1998: Jessica L Teeling; Els R de Groot; Anke J M Eerenberg; Wim K Bleeker; Gerard van Mierlo; Lucien A Aarden; C Erik Hack
Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro.
Clinical and experimental immunology 1998;114(2):264-70.
1998: HC van Zaanen; Henk M Lokhorst; Lucien A Aarden; H J Rensink; SO Warnaar; J van der Lelie; Marinus H J van Oers
Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.
British journal of haematology 1998;102(3):783-90.
1998: Claudia Verhagen; Tineke C T M van der Pouw Kraan; Anita A M Buffing; MA Chand; William R Faber; Lucien A Aarden; Pranab K Das
Type 1- and type 2-like lesional skin-derived Mycobacterium leprae-responsive T cell clones are characterized by coexpression of IFN-gamma/TNF-alpha and IL-4/IL-5/IL-13, respectively.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(5):2380-7.
1998: LM Liem; T van Lopik; Annemarie E M van Nieuwenhuijze; HC van Houwelingen; Lucien A Aarden; Els Goulmy
Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections.
Blood 1998;91(4):1464-8.
1998: Tineke C T M van der Pouw Kraan; jaring s. van der zee; LC Boeije; Els R de Groot; Steven O Stapel; Lucien A Aarden
The role of IL-13 in IgE synthesis by allergic asthma patients.
Clinical and experimental immunology 1998;111(1):129-35.
1997: HC van Zaanen; Johannes A Romijn; Hans P Sauerwein; Henk M Lokhorst; SO Warnaar; Lucien A Aarden; Erik Endert; Marinus H J van Oers
Modulation of chronic excessive interleukin-6 production in multiple myeloma does not affect thyroid hormone concentrations.
Metabolism: clinical and experimental 1997;46(11):1343-8.
1997: Tineke C T M van der Pouw Kraan; LC Boeije; Els R de Groot; Steven O Stapel; A Snijders; Martien L Kapsenberg; jaring s. van der zee; Lucien A Aarden
Reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(11):5560-5.
1996: Tineke C T M van der Pouw Kraan; LC Boeije; A Snijders; R J Smeenk; J Wijdenes; Lucien A Aarden
Regulation of IL-12 production by human monocytes and the influence of prostaglandin E2.
Annals of the New York Academy of Sciences 1996;795():147-57.
1996: J P Brakenhoff; H K Bos; Joachim Grötzinger; Stefan Rose-John; Lucien A Aarden
Identification of residues in the putative 5th helical region of human interleukin-6, important for activation of the IL-6 signal transducer, gp130.
FEBS letters 1996;395(2-3):235-40.
1996: H C van Zaanen; R P Koopmans; Lucien A Aarden; H J Rensink; J M Stouthard; S O Warnaar; Henk M Lokhorst; Marinus H J van Oers
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.
The Journal of clinical investigation 1996;98(6):1441-8.
1996: PM Jansen; T C van der Pouw Kraan; I W de Jong; Geertje J D van Mierlo; J Wijdenes; A A Chang; Lucien A Aarden; Fletcher B Taylor; C Erik Hack
Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon-gamma.
Blood 1996;87(12):5144-51.
1996: PM Jansen; I W de Jong; M Hart; K J Kim; Lucien A Aarden; L B Hinshaw; Fletcher B Taylor; C Erik Hack
Release of leukemia inhibitory factor in primate sepsis. Analysis of the role of TNF-alpha.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(11):4401-7.
1996: A Civil; Arjen Bakker; I Rensink; S Doerre; Lucien A Aarden; Cornelis L Verweij
Nuclear appearance of a factor that binds the CD28 response element within the interleukin-2 enhancer correlates with interleukin-2 production.
The Journal of biological chemistry 1996;271(14):8321-7.
1996: Tineke C T M van der Pouw Kraan; LC Boeije; J T Troon; S K Rutschmann; J Wijdenes; Lucien A Aarden
Human IL-13 production is negatively influenced by CD3 engagement. Enhancement of IL-13 production by cyclosporin A.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(5):1818-23.
1996: A Snijders; Catharien M U Hilkens; Tineke C T M van der Pouw Kraan; M Engel; Lucien A Aarden; Martien L Kapsenberg
Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(3):1207-12.
1996: Tom van der Poll; J Jansen; Marcel Levi; Hugo ten Cate; C Erik Hack; Lucien A Aarden; JW ten Cate; Sander J H van Deventer
Interleukin 10 release during endotoxaemia in chimpanzees: role of platelet-activating factor and interleukin 6.
Scandinavian journal of immunology 1996;43(1):122-5.
1995: F D de Hon; H K Klaasse Bos; S B Ebeling; Joachim Grötzinger; G Kurapkat; Stefan Rose-John; Lucien A Aarden; J P Brakenhoff
Leucine-58 in the putative 5th helical region of human interleukin (IL)-6 is important for activation of the IL-6 signal transducer, gp130.
FEBS letters 1995;369(2-3):187-91.
1995: J P Brakenhoff; F D de Hon; Lucien A Aarden
Development of human IL-6 receptor antagonists.
Annals of the New York Academy of Sciences 1995;762():129-34; discussion 135.
1995: C T Van der Pouw-Kraan; H J Rensink; R Rappuoli; Lucien A Aarden
Co-stimulation of T cells via CD28 inhibits human IgE production; reversal by pertussis toxin.
Clinical and experimental immunology 1995;99(3):473-8.
1995: Tineke C T M van der Pouw Kraan; LC Boeije; R J Smeenk; J Wijdenes; Lucien A Aarden
Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.
The Journal of experimental medicine 1995;181(2):775-9.
1994: F D de Hon; Marc Ehlers; Stefan Rose-John; S B Ebeling; H K Bos; Lucien A Aarden; J P Brakenhoff
Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells.
The Journal of experimental medicine 1994;180(6):2395-400.
1994: C T van der Pouw Kraan; R C Aalberse; Lucien A Aarden
IgE production in atopic patients is not related to IL-4 production.
Clinical and experimental immunology 1994;97(2):254-9.
1994: J P Brakenhoff; F D de Hon; V Fontaine; E ten Boekel; H Schooltink; Stefan Rose-John; Peter C Heinrich; Jean Content; Lucien A Aarden
Development of a human interleukin-6 receptor antagonist.
The Journal of biological chemistry 1994;269(1):86-93.
1993: D van Leenen; Tom van der Poll; Marcel Levi; Hugo ten Cate; Sander J H van Deventer; C Erik Hack; Lucien A Aarden; JW ten Cate
Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(4):2318-25.
1992: A Civil; M Geerts; Lucien A Aarden; Cornelis L Verweij
Evidence for a role of CD28RE as a response element for distinct mitogenic T cell activation signals.
European journal of immunology 1992;22(11):3041-3.
1992: P W Parren; P A Warmerdam; LC Boeije; J Arts; N A Westerdaal; A Vlug; PJ Capel; Lucien A Aarden; Jan G J van de Winkel
On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2.
The Journal of clinical investigation 1992;90(4):1537-46.
1992: P A Warmerdam; P W Parren; A Vlug; Lucien A Aarden; Jan G J van de Winkel; PJ Capel
Polymorphism of the human Fc gamma receptor II (CD32): molecular basis and functional aspects.
Immunobiology 1992;185(2-4):175-82.
1992: C Erik Hack; M Hart; R J van Schijndel; A J Eerenberg; J H Nuijens; Lambertus G Thijs; Lucien A Aarden
Interleukin-8 in sepsis: relation to shock and inflammatory mediators.
Infection and immunity 1992;60(7):2835-42.
1992: Tom van der Poll; Sander J H van Deventer; C Erik Hack; Gertjan Wolbink; Lucien A Aarden; Harry R Büller; JW ten Cate
Effects on leukocytes after injection of tumor necrosis factor into healthy humans.
Blood 1992;79(3):693-8.
1992: P W Parren; P A Warmerdam; LC Boeije; PJ Capel; Jan G J van de Winkel; Lucien A Aarden
Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(3):695-701.
1991: P W Parren; M E Geerts; LC Boeije; Lucien A Aarden
Induction of T-cell proliferation by recombinant mouse and chimeric mouse/human anti-CD3 monoclonal antibodies.
Research in immunology 1991;142(9):749-63.
1991: Cornelis L Verweij; M Geerts; Lucien A Aarden
Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-kB-like response element.
The Journal of biological chemistry 1991;266(22):14179-82.
1991: René A W van Lier; Mieke C Brouwer; E D De Groot; I Kramer; Lucien A Aarden; Arthur J Verhoeven
T cell receptor/CD3 and CD28 use distinct intracellular signaling pathways.
European journal of immunology 1991;21(7):1775-8.
1991: M W Nijsten; C Erik Hack; M Helle; Henk Jan ten Duis; HJ Klasen; Lucien A Aarden
Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients.
Surgery 1991;109(6):761-7.
1991: T Van der Pouw-Kraan; C Van Kooten; R Van Oers; Lucien A Aarden
Human transferrin allows efficient IgE production by anti-CD3-stimulated human lymphocytes at low cell densities.
European journal of immunology 1991;21(2):385-90.
1990: S J van Deventer; H R Büller; JW ten Cate; Lucien A Aarden; C E Hack; Augueste Sturk
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways.
Blood 1990;76(12):2520-6.
1990: K J Parleviet; M Jonker; R J ten Berge; R A van Lier; J M Wilmink; P F Strengers; Lucien A Aarden; P T A Schellekens
Anti-CD3 murine monoclonal isotype switch variants tested for toxicity and immunologic monitoring in four chimpanzees.
Transplantation 1990;50(5):889-92.
1990: J P Brakenhoff; M Hart; Els R de Groot; F Di Padova; Lucien A Aarden
Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(2):561-8.
1990: C Van Kooten; Marinus H J van Oers; Lucien A Aarden
Interleukin-6 enhances human Ig production, but not as a terminal differentiation factor for B lymphocytes.
Research in immunology 1990;141(4-5):341-56.
1989: C Ellen van der Schoot; P Jansen; M Poorter; M R Wester; Albert E G Kr von dem Borne; Lucien A Aarden; R H van Oers
Interleukin-6 and interleukin-1 production in acute leukemia with monocytoid differentiation.
Blood 1989;74(6):2081-7.
1989: C Erik Hack; E R De Groot; R J Felt-Bersma; J H Nuijens; R J M Strack van Schijndel; A J Eerenberg-Belmer; Lambertus G Thijs; Lucien A Aarden
Increased plasma levels of interleukin-6 in sepsis.
Blood 1989;74(5):1704-10.
1989: René A W van Lier; Mieke C Brouwer; Vivienne Rebel; Carel J M van Noesel; Lucien A Aarden
Immobilized anti-CD3 monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation and helper activity in human T lymphocytes.
Immunology 1989;68(1):45-50.
1989: J P Brakenhoff; M Hart; Lucien A Aarden
Analysis of human IL-6 mutants expressed in Escherichia coli. Biologic activities are not affected by deletion of amino acids 1-28.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(4):1175-82.
1989: M Helle; LC Boeije; Lucien A Aarden
IL-6 is an intermediate in IL-1-induced thymocyte proliferation.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(12):4335-8.
1989: J H Boot; M E Geerts; Lucien A Aarden
Functional polymorphisms of Fc receptors in human monocyte-mediated cytotoxicity towards erythrocytes induced by murine isotype switch variants.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(4):1217-23.
1988: M Helle; LC Boeije; Lucien A Aarden
Functional discrimination between interleukin 6 and interleukin 1.
European journal of immunology 1988;18(10):1535-40.
1988: R W Sauerwein; Menno A de Rie; W G van der Meer; Frank Miedema; Lucien A Aarden
Regulation of malignant B-cell proliferation by direct binding of anti-HLA class-II antibodies.
Cellular immunology 1988;114(2):424-31.
1988: Carel J M van Noesel; Frank Miedema; Mieke C Brouwer; Menno A de Rie; Lucien A Aarden; René A W van Lier
Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation.
Nature 1988;333(6176):850-2.
1988: M Helle; J P Brakenhoff; Els R de Groot; Lucien A Aarden
Interleukin 6 is involved in interleukin 1-induced activities.
European journal of immunology 1988;18(6):957-9.
1988: J H Boot; M E Geerts; Els R de Groot; Lucien A Aarden
Murine monoclonal isotype switch variants. Detection with rat monoclonal antibodies in ELISA and isolation by sequential sublining.
Journal of immunological methods 1988;106(2):195-202.
1988: Marinus H J van Oers; A A Van der Heyden; Lucien A Aarden
Interleukin 6 (IL-6) in serum and urine of renal transplant recipients.
Clinical and experimental immunology 1988;71(2):314-9.
1988: R W Sauerwein; W G van der Meer; T Logtenberg; Lucien A Aarden
Analysis of T-cell-derived factors with the use of B-prolymphocytic leukemia cells.
Clinical immunology and immunopathology 1988;46(1):1-13.
1988: R W Sauerwein; W G Van der Meer; J W Van Oostveen; Frank Miedema; Lucien A Aarden
Anti-CD3 antibodies induce T helper function for human B cell differentiation in vitro by an interleukin 2-independent pathway.
European journal of immunology 1988;18(1):133-7.
1987: J P Brakenhoff; Els R de Groot; R F Evers; Hans Pannekoek; Lucien A Aarden
Molecular cloning and expression of hybridoma growth factor in Escherichia coli.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(12):4116-21.
1987: René A W van Lier; J H Boot; Arthur J Verhoeven; Els R de Groot; Mieke C Brouwer; Lucien A Aarden
Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell-independent induction of interleukin 2 responsiveness in T cells by epsilon-anti-CD3.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(9):2873-9.
1987: René A W van Lier; J H Boot; Els R de Groot; Lucien A Aarden
Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems.
European journal of immunology 1987;17(11):1599-604.
1987: J H Boot; M E Geerts; Lucien A Aarden
Monoclonal anti-peroxidase isotype switch variants. Applications in studies of protein A binding and characterization of rat monoclonal antibodies.
Journal of immunological methods 1987;103(1):69-77.
1987: Gijs A van Seventer; K C Kuijpers; René A W van Lier; Els R de Groot; Lucien A Aarden; Cornelis J M Melief
Mechanism of inhibition and induction of cytolytic activity in cytotoxic T lymphocytes by CD3 monoclonal antibodies.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(8):2545-50.
1987: Lucien A Aarden; Els R de Groot; O L Schaap; P M Lansdorp
Production of hybridoma growth factor by human monocytes.
European journal of immunology 1987;17(10):1411-6.
1987: R W Sauerwein; W G van der Meer; Lucien A Aarden
Induction of proliferation of B prolymphocytic leukemia cells by phorbol ester and native or recombinant interferon-gamma.
Blood 1987;70(3):670-5.
1987: R W Sauerwein; W G Van der Meer; Lucien A Aarden
Analysis of T cell-replacing factor-like activity: potent induction of T helper activity for human B cells by residual concanavalin A and interleukin 2.
European journal of immunology 1987;17(8):1145-50.
1986: R W Sauerwein; Geert Mudde; W C Vooys; W G van der Meer; G C de Gast; Lucien A Aarden
Induction of IgM production by pokeweed mitogen and interleukin-2: different responses by human peripheral blood cells and tonsil cells.
Clinical immunology and immunopathology 1986;39(3):431-41.
1985: R W Sauerwein; W G Van der Meer; A Dräger; Lucien A Aarden
Interleukin 2 induces T cell-dependent IgM production in human B cells.
European journal of immunology 1985;15(6):611-6.
1985: Frank Miedema; J W Van Oostveen; R W Sauerwein; F G Terpstra; Lucien A Aarden; C J Melief
Induction of immunoglobulin synthesis by interleukin 2 is T4+/T8- cell dependent. A role for interleukin 2 in the pokeweed mitogen-driven system.
European journal of immunology 1985;15(2):107-12.